Timothy DeVere Cook - 04 Nov 2022 Form 4 Insider Report for Athenex, Inc.

Role
Chief Business and Commercial Officer, Proprietary Drugs
Signature
/s/Steven Adams, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
04 Nov 2022
Net transactions value
+$500
Form type
4
Filing time
08 Nov 2022, 06:44:37 UTC
Previous filing
24 Oct 2022
Next filing
21 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNXQ Common Stock Award $500 +2,561 +12% $0.1952 23,376 04 Nov 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATNXQ Stock Option (Right to Buy) 70,000 04 Nov 2022 Common Stock 70,000 $17.29 Direct
holding ATNXQ Stock Option (Right to Buy) 30,000 04 Nov 2022 Common Stock 30,000 $10.26 Direct F2
holding ATNXQ Stock Option (Right to Buy) 9,000 04 Nov 2022 Common Stock 9,000 $3.56 Direct F3
holding ATNXQ Restricted Stock Units 6,750 04 Nov 2022 Common Stock 6,750 Direct F4, F5
holding ATNXQ Stock Option (Right to Buy) 75,000 04 Nov 2022 Common Stock 75,000 $0.6655 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
F2 This option vests in four equal annual installments beginning on August 27, 2021.
F3 This option vests in four equal annual installments beginning on September 16, 2022.
F4 Each restricted stock unit represents a contingent right to receive one share of stock.
F5 The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
F6 This option vests in four equal annual installments beginning on July 20, 2023.

Remarks:

Chief Business and Commercial Officer, Proprietary Drugs